KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma

KRAS oncogene is known as an “undruggable” target for decades, the mutation rate is about 20-25% in non-small cell lung cancer(NSCLC) [1]. Recently, preliminary data from a phase I clinical trial of the KRAS G12C inhibitor AMG510 were reported, showing the potential anti-tumor activity of AMG 510 as a monotherapy in NSCLC[2 ]. As the first KRAS agents to process and enter clinical trials, AMG510 undoubtedly breaks the "curse" and brings hope to patients with KRAS mutation. However, AMG510 is still in the early phase of clinical experiment, besides G12C is only one of the mutation subtypes in KRAS, optimal treatment str ategies for other mutation subtypes are still lacking.

Source: Lung Cancer - September 9, 2020 Category: Cancer & Oncology Authors: Ge Gao, Weiting Liao, Qizhi Ma, Benxia Zhang, Yue Chen, Yongsheng Wang Source Type: research